David Greenwood Net Worth

The estimated Net Worth of David Greenwood is at least $560 Thousand dollars as of 1 November 2021. Mr. Greenwood owns over 20,000 units of CohBar Inc stock worth over $17,200 and over the last 21 years he sold CWBR stock worth over $165,487. In addition, he makes $377,775 as Independent Director at CohBar Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Greenwood CWBR stock SEC Form 4 insiders trading

David has made over 5 trades of the CohBar Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of CWBR stock worth $8,600 on 1 November 2021.

The largest trade he's ever made was selling 34,005 units of CohBar Inc stock on 14 June 2011 worth over $145,541. On average, David trades about 2,202 units every 103 days since 2003. As of 1 November 2021 he still owns at least 40,000 units of CohBar Inc stock.

You can see the complete history of Mr. Greenwood stock trades at the bottom of the page.

David Greenwood biography

David Greenwood serves as Independent Director of the Company. Mr. Greenwood joined our Board in April 2019. Mr. Greenwood served on the board of directors of Corium International, Inc. (“Corium”), a commercial biopharmaceutical company, from December 2010 to November 2018. He also served as chairman of Corium’s board of directors from December 2014 to November 2018, as the executive chairman of its board of directors from June 2012 to December 2014. He is the former president, chief executive officer, chief financial officer and director of Geron Corporation, a biotechnology company in the fields of regenerative medicine and cancer, where he worked from 1995 until December 2011. He was previously chairman of the board of directors of Geron’s wholly-owned subsidiary, Geron Bio-Med Limited, chairman of the board of directors of Geron’s majority-owned subsidiary, TA Therapeutics, Ltd., and on the board of directors of ViaGen, Inc., Clone International and Parnell Pharmaceuticals Holdings Ltd. He also served on the Board of Regents for Pacific Lutheran University. From 1979 to 1995, Mr. Greenwood held various positions with J.P. Morgan Chase & Co., an international banking firm. Mr. Greenwood received his bachelor’s degree from Pacific Lutheran University and his M.B.A. from Harvard Business School. Our Board believes that Mr. Greenwood’s financial and business expertise in the biopharmaceutical industry qualify him to serve as a member of our Board.

What is the salary of David Greenwood?

As the Independent Director of CohBar Inc, the total compensation of David Greenwood at CohBar Inc is $377,775. There are 5 executives at CohBar Inc getting paid more, with Steven Engle having the highest compensation of $2,410,850.

How old is David Greenwood?

David Greenwood is 68, he's been the Independent Director of CohBar Inc since 2019. There are 3 older and 10 younger executives at CohBar Inc. The oldest executive at CohBar Inc is Albion Fitzgerald, 71, who is the Independent Chairman of the Board.

What's David Greenwood's mailing address?

David's mailing address filed with the SEC is C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK, CA, 94025.

Insiders trading at CohBar Inc

Over the last 7 years, insiders at CohBar Inc have traded over $0 worth of CohBar Inc stock and bought 586,523 units worth $136,480 . The most active insiders traders include Misha Petkevich, Kenneth C Cundy, and Jon Leland Stern. On average, CohBar Inc executives and independent directors trade stock every 22 days with the average trade being worth of $9,727. The most recent stock trade was executed by David Greenwood on 1 November 2021, trading 20,000 units of CWBR stock currently worth $8,600.

What does CohBar Inc do?

cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.

Complete history of Mr. Greenwood stock trades at Geron and CohBar Inc

CohBar Inc executives and stock owners

CohBar Inc executives and other stock owners filed with the SEC include:

• Steven Engle,
  Chief Executive Officer, Director
• Phyllis Gardner,
  Independent Director
• Dr. Kenneth C. Cundy,
  Chief Scientific Officer
• Jeffrey F. Biunno CPA, M.B.A., CPA, MBA,
  CFO, Treasurer & Sec.
• Kenneth Cundy,
  Chief Scientific Officer
• David Greenwood,
  Independent Director
• Jeffrey Biunno,
  Chief Financial Officer, Treasurer, Secretary
• Jon Stern,
  Director
• Misha Petkevich,
  Independent Director
• Albion Fitzgerald,
  Independent Chairman of the Board
• Pinchas Cohen,
  Independent Director
• Nir Barzilai,
  Independent Director
• Jordyn Tarazi,
  Director of Investor Relations
• Dr. Rohit Loomba,
  Scientific Consultant
• Dr. Changhan David Lee Ph.D.,
  Consultant of Mitochondrial Biology
• Dr. David Andrew Sinclair A.O., Ph.D.,
  Co-Founder, Advisor & Consultant
• Dr. Joseph J. Sarret,
  CEO & Director
• Simon Allen,
  Chief Executive Officer
• Marc E. Goldberg,
  
• Philippe Calais,
  Director
• Joseph J. Sarret,
  Chief Executive Officer
• John Amatruda,
  Director
• Carol Nast,
  Director
• Joanne Yun,
  Director
• Stephanie Tozzo,
  Director